Public awareness and education campaigns regarding asthma and COPD are major market drivers for the medications used to treat these respiratory diseases. These campaigns result in earlier diagnosis and treatment, which is important in avoiding complications and enhancing long-term outcomes for patients. Therefore, increasing awareness of COPD and asthma is fueling the market size growth exceeding USD 40.49 Billion in 2024 to reach a value of USD 72.67 Billion by 2035
The focus on early intervention strategies is generating an increasing need for drugs that are used to control asthma and COPD effectively right from the onset of symptoms. It is improving patient care by providing timely access to the right treatments. Therefore, the early intervention strategies are facilitating the growth of the market to increase at a CAGR of 13.45% during the period 2024-2035
Click below to get a FREE SAMPLE REPORT-
https://www.marketinsightsresearch.com/request/download/9/38290/Asthma-And-COPD-Drugs-Market
How Increasing Generic Competition and Stringent Regulatory Norms is Hindering the Expansion of the Asthma and COPD Medicines Market?
Growing generic competition in the marketplace is constraining the growth market. When patents on major drugs run out, generic versions of the drugs become available, usually at a lower price. This competition can constrain revenue growth for branded pharmaceutical firms, as healthcare providers and patients turn to cheaper generic versions. Stringent regulatory requirements are another significant barrier. The strict requirements for the approval of new COPD and asthma drugs, particularly new therapies and biologics, can cause delay in market launch and add costs to development. This regulatory scenario can retard the launch of new treatments and elevate the economic cost to pharmaceutical companies.
Safety and side effects with some asthma and COPD drugs also impact their utilization. Drugs that have risks of cardiovascular problems or respiratory side effects may cause hesitation on the part of patients and practitioners to use them, thus limiting the market opportunity for these medicines. The expensive nature of some treatments, especially biologics and newer drugs, acts as a barrier to access for most patients. In areas with poor healthcare infrastructure or poor insurance coverage, the cost of these medications can be exorbitant, slowing down market growth as patients cannot afford essential medication.
Alternative therapeutic options for asthma and COPD can also influence demand for pharmaceutical treatment. Non-pharmacological treatments like pulmonary rehabilitation and lifestyle changes, including smoking cessation clinics, provide efficient management techniques that can decrease dependency on drugs. The presence and popularity of such alternatives can reduce the market opportunity for conventional drug therapies. The lack of proper awareness and knowledge about COPD and asthma among patients and healthcare providers can cause underdiagnosis or misdiagnosis. The absence of correct diagnosis may mean that patients receive inappropriate treatment, which can delay the development of the drug market. Awareness and education on these conditions are necessary to enable timely and proper diagnosis and treatment.
Asthma and COPD Drugs Market Report Highlights
| Aspects | Details |
 By DISEASES
|
|
 By MEDICATION CLASS
|
|
 By Region
|
|
 Key Market Players
|
Abbott Laboratories, AstraZeneca Plc, Novartis AG, Vectura Group Plc, Boehringer Ingelheim International GmbH, Organon, Teva Pharmaceutical Industries Ltd, Sanofi, Glaxosmithkline Plc, Hoffmann-La Roche Ltd
|
How the Rise in Prevalence of Respiratory Diseases across Region is Fuelling the Market Growth of Asthma and COPD Drugs Market in Asia Pacific Through the Forecast Period?
Asia Pacific will register the most rapid growth in Asthma and COPD Drugs Market in the forecast period. Increased respiratory diseases incidence in Asia Pacific is stimulated by various dominant factors. Accelerating urbanization and industrialization are creating an increasing number of atmospheric pollution phenomena, which have adverse effects on the progression of conditions such as asthma and COPD. Moreover, notwithstanding the declining rate in some industrialized nations, smoking is very common in large regions of Asia Pacific and strongly contributes to COPD burden. The aging populace of the region also contributes as a factor in that older patients are more likely to be victims of respiratory disorders, thus higher demand for medicines to treat COPD.
Furthermore, public health awareness campaigns have increased significantly, along with the development of healthcare infrastructure. The latter has helped in earlier detection and treatment of asthma and COPD, enhancing patient outcomes. There has also been economic growth in most of the Asian nations, leading to increases in disposable incomes among the population. Improved economic status gives people increased access to healthcare services and medication, including drugs for respiratory conditions.
In addition, governments in the region are proactively enacting healthcare policies to improve respiratory health. These include the establishment of reimbursement schemes to reduce the cost of asthma and COPD medications for patients. Moreover, large investments are being made in healthcare infrastructure, with new clinics and hospitals designed to diagnose and treat respiratory diseases efficiently. These efforts cumulatively support the development and expansion of the respiratory drugs market in Asia Pacific, with improved patient management and outcomes for those suffering from these diseases.
North America is Anticipated to Have a Substantial Market Share During the Forecast Period
The North American market is anticipated to lead the market for asthma and COPD drugs in the forecast period. This is due to increased disease incidence of conditions like COPD and asthma, aging population, growing research and development activities, and the presence of major market players.
The increasing incidence of Asthma and COPD in North American Nations is anticipated to drive the market growth. For example, the AAFA article in September 2022 stated that over 25 million individuals in the United States have asthma. And an NIH article released in March 2022 stated that in the United States, COPD has affected over 15 million adults. Likewise, asthma is among the significant public health issues in Canada that is anticipated to drive the growth of the researched market. As per the Statistics Canada statistics released in August 2022, more than 2,802,700 asthma cases were reported in Canada. The large number of patients suffering from asthma drives the demand for medicines for the treatment of the target disease, thus fueling the growth of this region.
Additionally, the increasing number of fundings carried out by government and non-government agencies is anticipated to enhance market growth in this region. For example, in March 2022, United States federal health programs released a bill that comprises USD 8.5 billion to sustain support for CDC asthma programs. This includes USD 30 million for the National Asthma Control program. Such investments are likely to raise awareness regarding asthma, which will enhance the use of drugs in asthma treatment, resulting in verticle growth.
